Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
about
The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected KoreansMolecular mechanisms underlying occult hepatitis B virus infection.Characteristics of Hepatitis B Co-infection and Disease Evolution in HIV-Positive Paediatric Patients in RomaniaYouth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconvertersHIV/HBV coinfection in children and antiviral therapy.The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans.Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapyRole of inflammation in HIV-1 disease progression and prognosis.Emerging challenges in managing hepatitis B in HIV patients.Dual antiretroviral therapy for HIV infection.Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa.Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.Human immunodeficiency virus and hepatitis C virus coinfection: the agenda is full while waiting for new drugs.Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
P2860
Q26781379-54AAC918-C14E-4AD0-8C0F-1441ABAD8AA8Q27686923-366982A8-04DA-4370-B445-9EC6861310D9Q33973843-75BB1725-2E81-4335-8979-11EF2C1FD6E6Q34030735-FE561A76-06FF-4BAC-95F9-CFAFD75FF52AQ35628651-AF805C1E-644E-40C5-8FE0-2D7E0C0DCECAQ36775147-E7706AF7-0A28-430D-81E9-EDC363DF03F6Q37518294-BBF4191D-9366-49C6-9D6A-671A8B3CDEA4Q37632321-6D1F0C20-0AC0-4094-AEA7-6A5256008C57Q38183454-EE61B014-78D9-4F65-B04E-148D2BFAA3BEQ38544189-8B7D6425-0C5E-4CF5-BD63-02B4EF25ADC1Q38670305-EC11D90C-56D2-440C-8880-EF93236BC5D5Q38918596-AF165648-A2FE-4320-8AAE-8455D74279E2Q45324809-6DB8FAEF-E68F-48AC-BF99-F5A7D62CC81CQ45355192-01D1BD21-C5BD-4717-94D9-608C25EFCD74Q45356161-3D5F39F9-ABF3-4DE0-9916-3B09269519CBQ46243261-5D6EB9F0-D5FF-41C2-9383-2FC510E74050
P2860
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Frequent hepatitis B virus reb ...... troviral therapy interruption.
@ast
Frequent hepatitis B virus reb ...... troviral therapy interruption.
@en
type
label
Frequent hepatitis B virus reb ...... troviral therapy interruption.
@ast
Frequent hepatitis B virus reb ...... troviral therapy interruption.
@en
prefLabel
Frequent hepatitis B virus reb ...... troviral therapy interruption.
@ast
Frequent hepatitis B virus reb ...... troviral therapy interruption.
@en
P2093
P2860
P50
P1433
P1476
Frequent hepatitis B virus reb ...... troviral therapy interruption.
@en
P2093
Bernd Kupfer
Ellen Tedaldi
Gregory J Dore
Jacqueline Neuhaus
Lars Peters
Marina B Klein
Massimo Puoti
SMART INSIGHT study group
P2860
P304
P356
10.1097/QAD.0B013E328334BDDB
P407
P577
2010-03-01T00:00:00Z